The fiercely competitive drug discovery industry continues to face many challenges, including regulatory hurdles, increasing costs of development, translational research and return on investment. These challenges have compelled many companies to look outside their own R&D function for contract partners to support research and development at the earliest stages of the drug discovery process. In less than 10 years, DIVERCHIM has become the first French CRO in chemistry for life science. Diver...